evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

Alemtuzumab 24 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).

1 finding from 1 review